
Researchers activate chemotherapeutics by ultrasound
Chemotherapeutic treatments produce strong side effects. A new drug complex that accumulates in the tumour tissue and is only activated there by...

Wacker AG expands biotech business through €100m acquisition
Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

German-Chinese ADC collaboration
Under the terms of the agreement, DualityBio (Shanghai) cashes in $170m upfront plus potential milestones of about $1.5bn. Additionally, DualityBio...

Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

Bayer AG is joining forces with Acuitas Therapeutics, Inc
Following the opening of an cell and gene therapy centre in the US, German Bayer AG opts for joining forces with Acuitas Therapeutics, Inc., a ...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...